Table 2 Results of clinical activity for immune checkpoint inhibitors in lung cancer

CTLA-4

Ipilimumab

IgG1

204

II

Phased ipilimumab: irPFS: 5.7 months; PFS: 5.1 months; Median OS: 12.2 months. Concurrent ipilimumab: irPFS: 5.5 months; PFS: 4.1 months; Median OS: 9.7 months. Control: irPFS: 4.6 months; PFS: 4.2 months; Median OS: 8.3 months [90].

Tremelimumab

IgG2

87

II

ORR: 4.8 %; PFS: 20.9 % vs. 14.3 % with supportive care [91].

29

II

Disease control: 31 % of patients, Median PFS: 6.2 months; Median OS: 10.7 months [92].

PD-1

Nivolumab

IgG4

129

I

Median OS across doses: 9.9 months; Median OS: 14.9 months at 3 mg/kg vs 9.2 at 1&10 mg/kg; ORR: 3 (1 mg/kg), 24 (3 mg/kg), and 20 % (10 mg/kg). 1-year OS rates at 3 mg/kg: 56 % [99].

117

II

PR: 14.5 % of patients; Stable disease: 26 % of patients; Median duration: 6 months; Median OS: 8.2 months; 1-year OS rates: 40.8 % [100].

582

III

Median OS: 12.2 months vs 9.4 months with docetaxel; ORR: 19.2 % vs 12.4 % with docetaxel. Median DOR: 17.1 months vs 5.6 months docetaxel [101].

Pembrolizumab

IgG4

495

I

ORR: 19.4 %; Median DOR: 12.5 months; Median PFS: 3.7 Months; Median OS: 12 months [102].

PD-L1

Atezolizumab

IgG1

37

I

ORR: 24 %; 24-week PFS: 48 % [106].

667

II

ORR: 19 % when atezolizumab used as a first-line therapy vs 17 % when it was a second-line or subsequent therapy [107].

277

II

OS: 12.6 months with atezolizumab vs 9.7 with docetaxel; PFS: 2.7 months with atezolizumab vs 3 months with docetaxel; OR: 14.3 with atezolizumab vs 7.2 with docetaxel [108].

BMS-936559

IgG4

75

I

ORR: 10 %; Stable disease ≥24 weeks: 12 %; PFS at 24 weeks: 31 % [109].

MEDI4736

IgG1

200

I/II

ORR: 16 %; Disease control rate at 12 weeks: 42 % [110].